Explore

Reuters Reuters
Regeneron drops after skin cancer treatment fails late-stage trial

Regeneron drops after skin cancer treatment fails late-stage trial

By Christy Santhosh May 18 (Reuters) - Regeneron's shares fell 12% in morning trade on Monday after the company's experimental treatment missed the main goal in a late-stage trial for patients with a type of skin cancer.
Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement
Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact
Trendline Trendline
Agenus Publishes Promising Phase 1b Data on Botensilimab and Balstilimab for Liver Cancer Patients

Agenus Publishes Promising Phase 1b Data on Botensilimab and Balstilimab for Liver Cancer Patients

Agenus Publishes Promising Phase 1b Data on Botensilimab and Balstilimab for Liver Cancer Patients
Trendline Trendline
Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins
Trendline Trendline
Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development

Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development

Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development
Trendline Trendline
Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations
Trendline Trendline
FDA Halts Aardvark Therapeutics' Prader-Willi Drug Trials Over Cardiac Concerns

FDA Halts Aardvark Therapeutics' Prader-Willi Drug Trials Over Cardiac Concerns

FDA Halts Aardvark Therapeutics' Prader-Willi Drug Trials Over Cardiac Concerns
Trendline Trendline
Atisama Therapeutics Advances RB042 in Phase 1 Trial and Appoints New Board Chair

Atisama Therapeutics Advances RB042 in Phase 1 Trial and Appoints New Board Chair

Atisama Therapeutics Advances RB042 in Phase 1 Trial and Appoints New Board Chair
Trendline Trendline
Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026

Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026

Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026